Michelle Green: Comprehensive Genomic Profiling as a Critical tool for detecting Important Biomarker
Michelle Green, Senior Manager, Oncology Genomics Program at
“Check out the latest paper from our group!
In this study, Labcorp reported rates of clinically relevant biomarker findings from over 20,000 solid tumor specimens analyzed with our flagship comprehensive genomic and immune profiling assay OmniSeq INSIGHT.
Findings highlight that a multi-modal approach combining DNA sequencing, RNA sequencing, RNA immune gene expression, and immunohistochemistry results in maximal biomarker detection with a high rate of test success while optimizing tissue usage.
Proud to contribute to the growing body of evidence supporting comprehensive genomic profiling (CGP) as a critical tool for detecting these important biomarkers, and congrats to all the authors, this was a big team effort!”
Utilization of a Multi-modal Comprehensive Genomic and Immune Profiling Testing Strategy Results in a High Rate of Test Success and Detection of Clinically Relevant Biomarkers While Optimizing Tissue Usage.
Authors: Michelle F. Green, Zachary D. Wallen, Heidi C. Ko, Kyle C. Strickland, Alicia Dillard, Jeffrey M. Conroy, Durga P. Dash, Mary K. Nesline, Paul DePietro, Shengle Zhang, Kamal S. Saini, Pratheesh Sathyan, Marcia Eisenberg, Brian Caveney, Shakti Ramkissoon, Eric A Severson and Rebecca A. Previs.
You can read the full article on Journal of Springer Nature Link.
More posts on Comprehensive Genomic Profiling on Oncodaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023